As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. Myriad understands the complexities and challenges you face in treating patients with cancer. That’s why we’ve developed innovative germline and somatic testing technologies that inform and identify treatment options for your patients—quickly and accurately.
Consolidated germline and somatic results, delivered fast
Reduced variant discordance by cross-checking between germline and somatic results
Simplified workflow solutions customizable to your practice
We are dedicated to delivering valuable and enriching research that will impact and shape the future of oncology. At the 2024 ASCO® Annual Meeting, our team of experts shared groundbreaking insights. Explore their work below to discover how our comprehensive testing solutions are transforming cancer care.
Prevention, risk reduction, and genetics
Gynecologic cancer
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Request more information about how Myriad’s Oncology solutions can benefit you/your patients.
You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.
Contact Information
Learn how Myriad is working to advance patient care through the Myriad Collaborative Research Registry—one of the largest pan-cancer registries freely available for research use.
Myriad’s Precise MRD test is whole genome sequencing (WGS)-based, enabling the custom selection of hundreds to thousands of targeted variants for deep analysis. It has impressive limits of detection and excellent sensitivity, ensuring exceptional performance. This test is currently available for research use only (RUO).
Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers.
Precise™ Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.
Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.
Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.
The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.
FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.
FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*
Offered together with Precise Tumor™ to measure protein expression and identify patients who may benefit from immunotherapy